Clinical trial

Campath-1H + FK506 and Methylprednisolone for GVHD

NCT00109993

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2005-01-01

PhasePHASE2

Study timeline

Study start (unknown)2005-01-01Date precision: month

Registry last updated2010-06-11

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Chronic Myeloproliferative Disordersunresolved

Gestational Trophoblastic Tumorunresolved

Graft Versus Host Diseaseunresolved

Leukemiaunresolved

Lymphomaunresolved

Multiple Myeloma and Plasma Cell Neoplasmunresolved

Myelodysplastic Syndromesunresolved

Myelodysplastic/Myeloproliferative Diseasesunresolved

Neuroblastomaunresolved

Ovarian Cancerunresolved

Testicular Germ Cell Tumorunresolved

Interventions

alemtuzumabBIOLOGICAL

methylprednisoloneDRUG · verified · RxNorm: methylprednisolone

tacrolimusDRUG · verified · RxNorm: tacrolimus

Sponsors & collaborators

Case Comprehensive Cancer Centerlead sponsor

National Cancer Institute (NCI)collaborator

Mapped research locations

ClevelandOhio, United States2 New YorkNew York, United States1 San AntonioTexas, United States1 PittsburghPennsylvania, United States1 PortlandOregon, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00109993 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.